Flutizal
Formulation

Flutizal® 25/125 Inhaler:

Each actuation delivers:

 
Salmeterol (as xinafoate) 25 mcg
Fluticasone propionate 125 mcg

 

Flutizal® 25/250 Inhaler:

Each actuation delivers:

 
Salmeterol (as xinafoate) 25 mcg
Fluticasone propionate 250 mcg

Salmeterol Xinafoate Fluticasone Propionate

Flutizal®

Prescription Drug

Indications

Fluticasone propionate + Salbutamol xinafoate inhaler is indicated in the regular treatment of asthma where use of a combination (long acting beta-2 agonist and inhaled corticosteroid) is appropriate:

  • Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2 agonist or,
  • Patients already adequately controlled on both inhaled corticosteroids and long acting beta-2 agonist.

Dosage and Administration

Adults and adolescents aged 12 years and older:

  • Fluticasone propionate + Salmeterol xinafoate 125/25 Inhaler: 2 inhalations (puffs) twice a day or,
  • Fluticasone propionate + Salmeterol xinafoate 250/25 Inhaler: 2 inhalations (puffs) twice a day or, as directed by the physician.

For more information on safety, precaution and other information about this product, please see the Product Insert.

Please consult your physician and other healthcare providers before taking any prescription medicines found on this site. The contents found on this page are for information purposes only. It should not be construed as a substitute for professional medical advise and should not be relied upon in that regard. You undertake to carefully read all product packaging and labels prior to use.

Caution: Food, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.